MicroRNA‐34a‐Dependent Attenuation of Angiogenesis in Right Ventricular Failure
Open Access
- 6 February 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (3) , e029427
Abstract
Background: The right ventricle (RV) is at risk in patients with complex congenital heart disease involving right‐sided obstructive lesions. We have shown that capillary rarefaction occurs early in the pressure‐loaded RV. Here we test the hypothesis that microRNA (miR)‐34a, which is induced in RV hypertrophy and RV failure (RVF), blocks the hypoxia‐inducible factor‐1α‐vascular endothelial growth factor (VEGF) axis, leading to the attenuated angiogenic response and increased susceptibility to RV failure. Methods and Results: Mice underwent pulmonary artery banding to induce RV hypertrophy and RVF. Capillary rarefaction occurred immediately. Although hypoxia‐inducible factor‐1α expression increased (0.12±0.01 versus 0.22±0.03, P =0.05), VEGF expression decreased (0.61±0.03 versus 0.22±0.05, P =0.01). miR‐34a expression was most upregulated in fibroblasts (4‐fold), but also in cardiomyocytes and endothelial cells (2‐fold). Overexpression of miR‐34a in endothelial cells increased cell senescence (10±3% versus 22±2%, P <0.05) by suppressing sirtulin 1 expression, and decreased tube formation by 50% via suppression of hypoxia‐inducible factor‐1α, VEGF A, VEGF B, and VEGF receptor 2. miR‐34a was induced by stretch, transforming growth factor‐β1, adrenergic stimulation, and hypoxia in cardiac fibroblasts and cardiomyocytes. In mice with RVF, locked nucleic acid‐antimiR‐34a improved RV shortening fraction and survival half‐time and restored capillarity and VEGF expression. In children with congenital heart disease–related RVF, RV capillarity was decreased and miR‐34a increased 5‐fold. Conclusions: In summary, miR‐34a from fibroblasts, cardiomyocytes, and endothelial cells mediates capillary rarefaction by suppressing the hypoxia‐inducible factor‐1α‐VEGF axis in RV hypertrophy/RVF, raising the potential for anti‐miR‐34a therapeutics in patients with at‐risk RVs.Keywords
This publication has 55 references indexed in Scilit:
- Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart functionProceedings of the National Academy of Sciences, 2012
- Dynamic microRNA expression during the transition from right ventricular hypertrophy to failurePhysiological Genomics, 2012
- Impaired Mitochondrial Biogenesis Precedes Heart Failure in Right Ventricular Hypertrophy in Congenital Heart DiseaseCirculation: Heart Failure, 2011
- New directions in basic research in hypertrophy and heart failure: Relevance for pediatric cardiologyProgress in Pediatric Cardiology, 2011
- Right and Left Ventricular Myocardial Perfusion Reserves Correlate with Right Ventricular Function and Pulmonary Hemodynamics in Patients with Pulmonary Arterial HypertensionRadiology, 2011
- Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop ReportAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Mitochondrial metabolic adaptation in right ventricular hypertrophy and failureJournal of Molecular Medicine, 2010
- Enalapril in Infants With Single VentricleCirculation, 2010
- Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- MicroRNA biogenesis: coordinated cropping and dicingNature Reviews Molecular Cell Biology, 2005